The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.
Chimeric Antigen Receptor T cells therapy (CAR-T) has revolutionized the course of disease of patients suffering from Refractory/ Resistant Hematologic malignancies. This success has now lead the FDA and EMA to approve rapidly these innovative cellular drugs.
Based on these unexpected and impressive results, the world of cellular immunotherapy offers new perspectives.
Mix and exchanges of people from different backgrounds (academics, scientists, pharmacists, clinicians, private companies…) will provide an excellent platform to help the development of CAR-T cells in France and worldwide in order to propose these innovative drugs to patients.
Introductive words, Sylvain Perruche, RIGHT Institute, Besançon, FR
Welcome words from the urban community’s President
Welcome words from the Region’s President
Introduction by Marco Ruella, UPENN, Philadelphia, USA
Chairmen: Christophe Ferrand and Marina Deschamps, RIGHT institute, Besançon, FR
Dr Philippe Boussot, Institut Pasteur, FR
Speaker to be confirmed, USA
Pr Huang He, Bone Marrow Transplantation Center, Zhejiang University, Hangzhou 310058, China; Institute of Hematology, Zhejiang University, Hangzhou 310058, China
Dr Álvaro Urbano Ispizua, Head of Hematology at the Clínic de Barcelona, Spain
Pr Roch Huo, Head of clinical Hematology, UMR INSERM U1236, Rennes, FR
Chairmen: Sylvain Perruche, RIGHT Institute, Besançon, FR
Eric Halioua, PDC*line Pharma, Liège, BE
Dr Miguel Forte , Bone Therapeutics, Charleroi, BE
Speaker to be confirmed, XX, xx,xx
Speaker to be confirmed, XX, xx,xx
Speaker to be confirmed, XX, xx,xx
Chairwoman: Dr Mathilde Girard, ADHARA, subsidiary of the URGO Group, Chenôve, FR
Emmanuel DEQUIER, « Grand défi Biomedicaments »,Secretariat Général pour l’Investissement, Paris, FR
Speaker to be confirmed, LFB Biomanufacturing, Alès, FR
Présidente ou VP to be confirmed, Jeito Capital, Paris, FR
Speaker to be confirmed, XX, xx,xx
Speaker to be confirmed, XX, xx,xx
Chairman : Philippe DULIEU, RD Biotech, Besançon, FR
Dr Carole HENRY, Moderna Cambridge, Massachusetts, USA
Bernard Sagaert, eTheRNA, Niel, BE
Speaker to be confirmed, Flash Therapeutics, Toulouse, FR
Dr Marco Alessandrini, Antion Biosciences , Geneva, CH
Pr Huang He – Institute of Hematology, Zhejiang University, (Hangzhou , China), Dr Philippe Boussot – Institut Pasteur (Paris,FR), Dr Álvaro Urbano Ispizua , Clínic de Barcelona (Barcelona, Spain), Pr Roch Huo, UMR INSERM U1236, (Rennes, FR), Marco Ruella – Center for Cellular Immunotherapies, U Penn (Philadelphia, USA) , Eric Halioua -PDC*line Pharma (Liège-Belgium) , Bernard Sagaert – eTheRNA immunotherapies NV (Niel, Belgium)
A doctor in biology, the Bisontinental Inserm researcher worked for nearly ten years within Inserm's Joint Research Unit 1098 - hosted by the Etablissement français du sang Bourgogne-Franche-Comté, in Besançon - in the development of therapeutic approaches to control the...
En savoir +Serial entrepreneur that combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising. During his career he achieved together with its different teams to bring four drug candidates from research to the clinics (up to...
En savoir +Since more than 20 years, I have been interested in the field of the T-cell response either after hematopoietic stem cell allo-transplantation or in the anti-tumor effect to modulate Graft versus Host disease (GvHD) or to initiate anti-tumoral effects (Graft...
En savoir +Bernard Sagaert, COO and Senior Vice President of eTheRNA, is an Industrial Pharmacist with extensive experience in the pharmaceutical industry. He has expertise in pharmaceutical authorizations, inspections and manufacturing. He was a former QA & Supply Chain Director at Mylan...
En savoir +Marco Ruella, MD, is Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. His research focuses on the study...
En savoir +CEO of Bone Therapeutics, Professor at the Lisbon University and Board of Directors and Executive Committee member for ARM and Board Member for Essenscia-Wallonie. President-Elect of ISCT from May 2022. Previously Chief Commercialization Officer and Chair of the ISCT Commercialization...
En savoir +Associate Professor in Biochemistry & Molecular Biology in the Sciences University of Franche-Comté (Besancon, Fr), Philippe Dulieu founded RD-BIOTECH SAS in 2002, with 2 post-doc fellows specialized in molecular biology and antibody engineering, Jean-Luc Schlick and Jean-François Musard. Since 2002,...
En savoir +From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor...
En savoir +Emmanuel Dequier is in charge of the French « Grand Défi Biomédicament » (National Challenge Biomedicines) whose objective is improving yields and control production costs. He previously held the position of Director of Research and Technology Platforms at Genopole, France's...
En savoir +